The American Journal of Clinical Nutrition, Volume 107, Issue 4, 1 April 2018, Pages 652–663, https://doi.org/10.1093/ajcn/nqx047
Beatriz Goulão Fiona Stewart John A Ford Graeme MacLennan Alison Avenell
- Dose Size: They gave 42% of the weight to a single trial with only 800 IU of vitamin D
- Probably because that single trial had the highest Cancer incidence
- Types - included Vitamin D2, active vitamin D, and Vitamin D analogs
- Vitamin D level achieved (which is a function of both dose size and trial duration)
- Vitamin D does not improve cancer survival much – when dose size, etc. is ignored – Oct 2015
- Similar to the study on this page
- Breast Cancer Mortality reduced 60 percent if more than 60 ng of Vitamin D – meta-analysis June 2017
- Evidence that Vitamin D prevents Cancer – Grant Feb 2018
- Dogs with Cancer have low vitamin D, same as humans – Sept 2017
- Cancer risk in older women reduced 32 percent by 2,000 IU of Vitamin D plus Calcium – 4 year RCT Oct 2016
- Cancer risk reduced 65 percent by vitamin D levels greater than 40 nanograms – April 2016
Cancer category starts with the following
176 items Overview Cancer and vitamin D
- After Cancer Diagnosis
- Bladder Cancer
- Breast Cancer
189 items Overview Breast Cancer and Vitamin D
- Colon Cancer
90 items Overview Cancer-Colon and vitamin D
- Lung Cancer
38 items Overview Lung cancer and vitamin D
- Lymphoma Cancer
- Prostate Cancer
78 items Prostate Cancer and Vitamin D studies
- Pancreatic Cancer
- Skin Cancer
96 items Overview Suntans melanoma and vitamin D
Background: Low 25-hydroxyvitamin D status has been associated with a higher risk of cancer in epidemiologic studies.
Objective: The aim of this study was to undertake a systematic review and meta-analysis of randomized clinical trials (RCTs) investigating the effect of vitamin D supplementation alone on cancer incidence and mortality.
A systematic review was undertaken. MEDLINE, Embase, CENTRAL, conference abstracts, and clinical trial registries were searched (last search March 2017) for RCTs investigating vitamin D supplementation alone. RCTs with ≥12 mo of follow-up and in participants with a mean or median age ≥60 y were eligible. During-study events were used as the main analysis, but after-study events were included in a secondary analysis. Subgroup analyses concerning different forms of vitamin D supplementation, 25-hydroxyvitamin D status at baseline, vitamin D dose, and exclusion of open-label trials were undertaken.
Thirty studies in 18,808 participants were included in the systematic review, with a median follow-up ranging from 1 to 6.2 y. The results of the meta-analysis for during-study events showed no evidence of an effect of vitamin D supplementation for cancer incidence (RR: 1.03; 95% CI: 0.91, 1.15) and cancer-related deaths (RR: 0.85; 95% CI: 0.70, 1.04). Including after-study events, the RRs were 1.02 (95% CI: 0.92, 1.13) and 0.85 (95% CI: 0.72, 1.00), respectively. These results did not appear to be affected by baseline 25-hydroxyvitamin D status, vitamin D dose, or the exclusion of open-label trials.
We did not find evidence to suggest that vitamin D supplementation alone reduces the incidence of cancer or cancer mortality, even after including long-term follow-up results.
158 visitors, last modified 09 Apr, 2018, URL:
- After Cancer Diagnosis